{
    "organizations": [],
    "uuid": "56c86bd8bd0fbb472581a42f5021dc46a5f54da3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cymabay-therapeutics-q1-loss-per-s/brief-cymabay-therapeutics-q1-loss-per-share-0-32-idUSASC0A0L6",
    "ord_in_thread": 0,
    "title": "BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - CymaBay Therapeutics Inc:\n* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* Q1 LOSS PER SHARE $0.32 * Q1 EARNINGS PER SHARE VIEW $-0.14 — THOMSON REUTERS I/B/E/S\n* QTRLY LOSS PER SHARE $0.32 * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $229.5 MILLION AT END OF Q1 OF 2018\n* EXISTING CASH IS EXPECTED TO FUND CYMABAY’S CURRENT OPERATING PLAN INTO 2021 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T06:46:00.000+03:00",
    "crawled": "2018-05-09T12:50:32.062+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cymabay",
        "therapeutic",
        "inc",
        "cymabay",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "qtrly",
        "loss",
        "per",
        "share",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "totaled",
        "million",
        "end",
        "q1",
        "existing",
        "cash",
        "expected",
        "fund",
        "cymabay",
        "current",
        "operating",
        "plan",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}